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2010). Nevertheless, the independent blinded assessments of passive
and active movement combined with the reported effect sizes are still
convincing to argue that a signiﬁcant change in muscle stiffness was in-
duced. Raghavan and colleagues must be complimented for their inno-
vative approach and carefully exploring this new treatment for muscle
stiffness, based on sound, but yet to be conﬁrmed reasoning. The poten-Central nervous system (CNS) diseases such as cerebral palsy (CP),
stroke (CVA), spinal cord injury (SCI) or multiple sclerosis (MS) often
engender impaired motor control that might affect the performance of
activities, to a level that requires intervention to improve the quality
of life for the patient. However, the heterogeneity of consequences of
the CNS disease and the complex nature of motor control makes it
hard to precisely identify the underlying impairments for each patient.
Additionally, effectively treating these chronic patients is limited by an
absence of proper treatment options for many of these underlying
impairments.
“Spasticity” is the usual clinical nomenclature to describe the in-
creased perceived resistance during passive elongation of the muscle
during physical examination. Although well recognized, this phenome-
non is poorly understood. Its etiology is considered to be either
hyperreﬂexia (Lance, 1980) as a response tomuscle stretch, or stiffened
muscular tissue (Lieber et al., 2004). Common clinical treatment regi-
mens focus on reducing the hyperactivation by chemical denervation
of the muscle (e.g., botulinum toxin) to weaken the muscle or rhizoto-
my of the dorsal roots to attenuate the reﬂex loop.
In the EBioMedicine paper by Raghavan et al. (2016), an alternative
approachwas presented, i.e. to target the increased stiffness of themus-
cular tissue, to release its restraining effects on execution of relevant
movements of the upper extremity. They postulated the hyaluronan hy-
pothesis, arguing that themain contributing factor tomuscle stiffness in
the chronic phase after stroke is an adaption of the muscular tissue
through the accumulation of hyaluronan. Injections with off-label
human recombinant hyaluronidase were used to counteract the effects
of hyaluronan and test the hypotheses in a case series trial.
Next to being a safe procedure a large effect was found on the so-
called modiﬁed Ashworth scale (MAS). This is a typically clinical phe-
nomenological 4 point ordinal scale that is used to score perceivedmus-
cle stiffness. Consequently the MAS does not inform on the etiology ofm.2016.05.014.
. This is an open access article undermuscle stiffness and was found to be not very reliable (Fleuren et al.,
tial efﬁcacy of hyaluronidase injections found warrants further study,
also in other disorders characterized by muscle stiffness.
Further studies should overcome the weaker points of the study of
Raghavan and colleagues as well as expand on our understanding
what causes stiffness in the muscle. Besides a controlled randomized
methodology, the next step should include more appropriate outcome
measures. Based on recent consensus on concepts of tissue stiffness
and hyperreﬂexia (Noort et al. 2016), instrumented assessments are de-
ﬁned to replace theMAS. Such assessments comprise themeasurement
of the joint moment and joint angle as a function of time during passive
elongation of the muscle, to quantify stiffness employing slow stretch.
Furthermore surface electromyographic signals are recorded, to quanti-
fy reﬂex activity, employing fast stretch (Bar-On et al., 2014). These
measureswill also help to identify the best responders to hyaluronidase,
since it is presumed to be effective in cases where tissue stiffness is the
main nominator of perceived hyper-resistance. Furthermore, next to
these structural outcomes, the assumed association between reducing
muscle stiffness (evaluated on the passive muscle) and meaningful
gains in functional outcomes of the upper paretic limb (involving active
contractions) needs further elaboration, e.g. using 3D kinematic evalua-
tion of relevant upper extremity tasks (Andel et al., 2008).
More fundamentally, as argued before related to Botulinum toxin for
upper limb spasticity (Gracies et al., 2015), studies are needed to estab-
lish how changes in the neuronal component of spasticity
(hyperreﬂexia) interact longitudinallywith the progressive biomechan-
ical muscle tissue changes in various disorders characterized by muscle
stiffness. Increased levels of muscular contractions will lead to muscle
tissue shortening and/or stiffening, while muscle spindles in stiff tissue
will bemore sensitive and lower the threshold of stretch reﬂexes, creat-
ing a self-promoting system. Raghavan and colleagues suggested sever-
almechanisms that need followupespecially to generate hypotheses on
the timing of the treatment.
The conventional treatment to counteract shortened/stiffened mus-
cle tissue is to apply long term stretch by means of progressive plaster-
ing or dynamic orthoses. Recently the response to such mechanically
applied long-term stretch was found to be effective by altering fasciclethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
24 J. Harlaar / EBioMedicine 9 (2016) 23–24strain (Theis et al., 2015). This has been found by applying 3D ultra-
sound imaging of the muscles, a promising technique to further reveal
morphological changes along with the external mechanical behavior.
The further use of microendoscopy (Cromie et al., 2013) will reveal in-
formation at the level of the sarcomere in stiffened muscles and the ef-
fect of hyaluronidase.
Overall, the study by Raghavan and colleagues have shown that in-
jections of hyaluronidase are safe to apply and results in reducedmuscle
stiffness of upper extremitymuscles formore than 3months after appli-
cation in the chronic stage in patients with cerebral injury. It is based on
a new paradigm on the etiology of muscle stiffness, which is promising
but will require extensive follow up to prove its accuracy and clinical
value.
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